Curaxin CBL0137 has the potential to reverse HIV-1 latency.
J Med Virol
; 91(8): 1571-1576, 2019 08.
Article
en En
| MEDLINE
| ID: mdl-30989696
ABSTRACT
A cure for human immunodeficiency virus type-1 (HIV-1) has been hampered by the limitation of current combination antiretroviral therapy (cART) to address the latent reservoirs in HIV-1 patients. One strategy proposed to eradicate these reservoirs is the "shock and kill" approach, where latency-reversing agents (LRAs) are used to reactivate and promote viral cell death and/or immune killing of reactivated cells. Here, we report that curaxin CBL0137, an antitumor compound, can potentiate tumor necrosis factor-α-mediated reactivation of latently infected HIV-1cell lines. Additionally, the single use of CBL0137 is sufficient to reactivate HIV-1 latent reservoirs in peripheral mononuclear cells (PBMCs) isolated from HIV-1 positive, cART-treated, aviremic patients. Thus, CBL0137 possesses capabilities as a LRA and could be considered for the "shock and kill" approach.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
2_ODS3
/
4_TD
Problema de salud:
2_enfermedades_transmissibles
/
4_aids
Asunto principal:
Activación Viral
/
Carbazoles
/
Infecciones por VIH
/
VIH-1
/
Latencia del Virus
Límite:
Humans
Idioma:
En
Revista:
J Med Virol
Año:
2019
Tipo del documento:
Article